RNS Number : 1105L MaxCyte, Inc. 01 September 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , September 1, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8348J MaxCyte, Inc. 18 August 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 6900J MaxCyte, Inc. 17 August 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 5609J MaxCyte, Inc. 17 August 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 9227I MaxCyte, Inc. 10 August 2023 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2023 ROCKVILLE, MD , August 10, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 8618I MaxCyte, Inc. 10 August 2023 MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD , August 10, 2023 — MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused
RNS Number : 6939I MaxCyte, Inc. 08 August 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 5553I MaxCyte, Inc. 07 August 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, Md. , August 07, 2023 -- MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 9132H MaxCyte, Inc. 01 August 2023 MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients Prime Medicine to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime
RNS Number : 8000H MaxCyte, Inc. 31 July 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , July 31, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
